TABLE 3. Estimated proportion of adults aged ≥50 years who ever received herpes zoster vaccination,* by age and race/ethnicity† — National Health Interview Survey, United States, 2018.
| Characteristic | Unweighted sample size | % (95% CI) | Vaccinated population size (weighted) | Simple difference from 2017 |
|---|---|---|---|---|
|
≥50 yrs
| ||||
|
Overall§
|
13,486 |
24.1
(23.1–25.1) |
26,687,664 |
0.2 |
|
Race/Ethnicity
| ||||
| White |
10,087 |
28.0
(26.9–29.1) |
22,290,713 |
0.4 |
| Black |
1,417 |
12.4
(10.6–14.5)¶ |
1,398,925 |
1.1 |
| Hispanic |
1,146 |
12.2
(10.0–14.7)¶ |
1,487,592 |
−0.1 |
| Asian |
509 |
19.6
(15.8–24.2)¶ |
1,062,651 |
−4.6 |
| Other |
327 |
19.8
(15.0–25.6)¶ |
447,783 |
1.3 |
|
≥60 yrs
| ||||
|
Overall
|
9,401 |
34.5
(33.2–35.8) |
24,356,476 |
−0.4 |
|
Race/Ethnicity
| ||||
| White |
7,231 |
38.6
(37.2–40.1) |
20,582,442 |
−0.7 |
| Black |
945 |
18.8
(16.0–21.9)¶ |
1,204,795 |
1.7 |
| Hispanic |
691 |
19.5
(15.9–23.8)¶ |
1,288,214 |
−0.4 |
| Asian |
332 |
29.1
(23.6–35.4)¶ |
893,689 |
−2.7 |
| Other |
202 |
30.9
(23.3–39.8) |
387,336 |
3.0 |
|
60–64 yrs | ||||
|
Total
|
2,310
|
22.5
(20.4–24.8)
|
4,681,477
|
0.1
|
| White |
1,761 |
25.4
(23.0–28.1) |
3,895,942 |
0.7 |
| Black |
241 |
10.8
(7.0–16.3)¶ |
225,333 |
−1.9 |
| Hispanic |
183 |
15.3
(8.9–24.9)¶ |
342,136 |
−2.0 |
| Asian |
73 |
19.7
(12.0–30.7) |
161,164 |
−2.6 |
| Other |
52 |
—§§ |
— |
— |
|
≥65 yrs
| ||||
|
Total
|
7,091
|
39.5
(37.9–41.1)
|
19,674,999
|
−0.8
|
| White |
5,470 |
44.0
(42.3–45.7) |
16,686,500 |
−1.0 |
| Black |
704 |
22.6
(19.2–26.4)¶ |
979,462 |
3.1 |
| Hispanic |
508 |
21.7
(17.8–26.3)¶ |
946,078 |
0.3 |
| Asian |
259 |
32.5
(25.8–40.1)¶ |
732,525 |
−4.3 |
| Other |
150 |
35.5
(26.2–46.1) |
330,434 |
4.2 |
|
Zoster vaccine live**
| ||||
| ≥50
yrs |
13,125 |
19.0
(18.1–20.0) |
20,583,161 |
−4.9¶¶ |
| 50–59
yrs |
4,062 |
3.7 (3.1–4.5) |
1,484,353 |
−2.0¶¶ |
| ≥60
yrs |
9,063 |
28.0
(26.8–29.3) |
19,098,808 |
−6.9¶¶ |
| 60–64
yrs |
2,268 |
17.7
(15.8–19.7) |
3,606,395 |
−4.8¶¶ |
| ≥65
yrs |
6,795 |
32.5
(31.0–34.0) |
15,492,413 |
−7.8¶¶ |
|
Recombinant zoster
vaccine††
| ||||
| ≥50
yrs |
13,211 |
2.4 (2.1–2.8) |
2,647,858 |
NA |
| 50–59
yrs |
4,063 |
1.0 (0.7–1.5) |
415,969 |
NA |
| ≥60
yrs |
9,148 |
3.3 (2.8–3.7) |
2,231,889 |
NA |
| 60–64
yrs |
2,277 |
2.6 (1.9–3.5) |
532,780 |
NA |
| ≥65
yrs |
6,871 |
3.5 (3.0–4.1) |
1,699,109 |
NA |
|
Recombinant zoster vaccine, received in 2018, at
least 2 doses
| ||||
| ≥50
yrs |
13,164 |
0.6 (0.5–0.8) |
653,911 |
NA |
| 50–59
yrs |
4,060 |
— |
— |
NA |
| ≥60
yrs |
9,104 |
0.8 (0.6–1.1) |
562,499 |
NA |
| 60–64
yrs |
2,271 |
— |
— |
NA |
| ≥65 yrs | 6,833 | 0.8 (0.6–1.1) | 391,474 | NA |
Abbreviations: CI = confidence interval; NA = not available.
* Respondents were asked if they had ever received a herpes zoster vaccine. Persons who answered “did not know” or “refused” for each of the “ever had” questions for any zoster vaccine (2.9%), zoster vaccine live (10.0%), and recombinant zoster vaccine (RZV) (7.6%) were excluded from the analysis.
† In this report, persons identified as White, Black, Asian, or other race are non-Hispanic. Persons identified as Hispanic might be of any race. “Other” includes American Indian/Alaska Native persons and persons who identified multiple races. The five racial/ethnic categories are mutually exclusive.
§ Respondents were asked if they had ever received a herpes zoster vaccine. Persons who answered “did not know” or “refused” for “ever had any zoster vaccine” (2.9%) were excluded from the analysis.
¶ p<0.05 by t–test for comparisons with non-Hispanic White as the reference.
** Respondents were asked if they had ever received a herpes zoster vaccine and, if yes, were asked if they ever had zoster vaccine live (requires 1 dose). Persons who answered “did not know” or “refused” for “ever had zoster vaccine live” (10.0%) were excluded from the analysis.
†† Respondents were asked if they had ever received a herpes zoster vaccine. If yes, respondents were asked if they ever had recombinant zoster vaccine (requires 2 doses) and, if yes, how many doses. Persons who answered “did not know” or “refused” for “ever had recombinant zoster vaccine (7.6%)” were excluded from the analysis.
§§ Estimate is not reliable because of small sample size (n < 30) or if relative standard error (standard error/estimates) was >0.3.
¶¶ p<0.05 by t-test for comparisons between 2017 and 2018 season within each level of each characteristic.